Atea Pharmaceuticals
AVIR
113 hedge funds and large institutions have $220M invested in Atea Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 39 reducing their positions, and 14 closing their positions.
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
30% more capital invested
Capital invested by funds: $170M → $220M (+$50.1M)
5% more funds holding
Funds holding: 108 → 113 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.93% less ownership
Funds ownership: 66.52% → 64.59% (-1.9%)
13% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 39
92% less call options, than puts
Call options by funds: $494K | Put options by funds: $6.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.68M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.37M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.14M |
| 4 |
Two Sigma Advisers
New York
|
+$1.01M |
| 5 |
Two Sigma Investments
New York
|
+$823K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.33M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.56M |
| 3 |
Morgan Stanley
New York
|
-$1.61M |
| 4 |
Renaissance Technologies
New York
|
-$1.46M |
| 5 |
BlackRock
New York
|
-$785K |
AVIR Hedge Fund Activity: Q1 2024 in Review
113 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2024, worth a combined $220M — up 30% from $170M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AVIR positions and 14 closed out — a net gain of 5 holders — while 34 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.68M. The largest seller was EcoR1 Capital, cutting an estimated $3.33M.
- 113 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2024, up from 108 in Q4 2023.
- Funds reported $220M of Atea Pharmaceuticals stock for Q1 2024, up 30% quarter-over-quarter.
- 19 funds opened new Atea Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +5 holders.
- The largest Atea Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $1.68M added.
- The largest Atea Pharmaceuticals seller in Q1 2024 was EcoR1 Capital, an estimated $3.33M sold.
Based on aggregated 13F filings for Q1 2024.